Anti-HER2 CAR-T / UTC Therap - LARVOL DELTA

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: UTC Therapeutics Inc. | Trial completion date: Nov 2027 ➔ Apr 2028 | Trial primary completion date: Nov 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • HER-2

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: UTC Therapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: UTC Therapeutics Inc.

New trial • Oncology • Solid Tumor